ACAD צמיחה צפויה ברווח למניה לשנה הבאה acadia-pharm.com

ACADIA Pharmaceuticals production cycles are based on stable interaction with contract manufacturing plants. Supply security to medical centers is ensured by strict pharmaceutical control. Forward earnings per share dynamics visualize market expectations, while 39.40 records a new level mark. Capitalization growth is driven by sales of Nuplazid and Daybue, as well as a promising portfolio of drugs for the treatment of rare brain pathologies.

When assessing the long-term sustainability of ACADIA Pharmaceuticals (ACAD), investors must weigh the market valuation against the expected earnings per share for the coming year, as illustrated by the consensus EPS n+1 forecast chart. This indicator measures the weighted average earnings growth rate based on analyst projections, making it possible to identify inflated expectations that could trigger a sharp price correction in the event of patent disputes over Nuplazid or rising costs for Daybue.